A retrospective study has shown that the procedure is feasible and was performed safely in selected patients with renal tumors.
Benjamin T Ristau, MD, and Robert G. Uzzo, MD, FACS, examine why adjuvant therapies have been so ineffective.
Estimated 33% of overall risk is genetic; certain types of cancer have additional risk.
Regular use of non-steroidal anti-inflammatory drugs for 10 years or more increased the risk of dying from renal cell carcinoma nearly 4-fold.
Patients who underwent upfront cytoreductive nephrectomy lived 6.4 months longer than those treated with upfront targeted therapy, a study found.
The protective effect was not observed with other anti-diabetic medications.
The drug nearly doubled the delay in tumor growth compared with everolimus.
Study reveals no significant differences in hospital readmission rates and overall, cancer-specific, and recurrence-free survival rates.
Nivolumab is cleared for treating patients with metastatic RCC whose disease advanced despite prior treatment with anti-angiogenic therapy.
For patients with diabetes, poor glycemic control linked to higher risk of post-operative progression.
Specific alterations seen in type 1 and type 2 carcinomas; type 2 consists of at least 3 subtypes.
Dialysis, organ transplant may increase odds for certain types of cancer.
High-heat cooking methods implicated in new study.
On-treatment neutropenia and hypertension are independently associated with decreased mortality risk.
Researchers report a survival advantage over observation among elderly patients with localized tumors.
Case report describes 84-year-old male patient with myositis after nivolumab treatment.
Higher stroke risk found in older kidney cancer patients taking the drugs.
The model incorporates 2 newly identified independent mortality risk factors in patients requiring second-line targeted therapy.
Active surveillance equal to partial nephrectomy for renal function preservation.
In separate studies, nivolumab prolonged overall survival and cabozantinib improved progression-free survival compared with everolimus.
Trend mirrors move to targeted therapy era.
Higher risk for clear cell, papillary renal cell carcinoma, but not chromophobe histology.
Increased risk for treatment-related subsequent neoplasms even beyond age 40 years.
Quality of life can be improved without adversely affecting outcomes.
New data suggest a prognosis role for the neutrophil to lymphocyte ratio.
Completely intracorporeal robotic level III inferior vena cava tumor thrombectomy viable.
Older adults react differently to treatment, oncology group notes.
Almost 1 in 3 not told cancer treatment might affect future fertility.
No improvement in quality of life, even for patients with good baseline performance status.
- Twice-Weekly Dialysis May Preserve Residual Kidney Function
- Robotic Nephrectomy of Kidney Tumors With Thrombi Feasible
- How to Prevent Sexual Transmission of Zika Virus
- Parathyroidectomy Cuts Mortality Risk in Patients With Severe SHPT
- Prostate Cancer Diagnosis Ups Risk of Non-Cancer Hospitalizations
Sign Up for Free e-newsletters
NEPHROLOGY & UROLOGY NEWS
- Acute Kidney Injury (AKI)
- Chronic Kidney Disease (CKD)
- Contrast Nephropathy
- Cardiovascular Disease (CVD)
- Diabetic Nephropathy
- End-stage Renal Disease (ESRD)
- Lupus Nephritis
- Peritoneal Dialysis
- Secondary Hyperparathyroidism (SHPT)